| 1. |
- Braito, V, et al.
(författare)
-
Dramatic Changes in the Observed Velocity of the Accretion Disk Wind in MCG-03-58-007 Are Revealed by XMM-Newton and NuSTAR
- 2022
-
Ingår i: Astrophysical Journal. - : American Astronomical Society. - 0004-637X .- 1538-4357. ; 926:2
-
Tidskriftsartikel (refereegranskat)abstract
- Past X-ray observations of the nearby Seyfert 2 MCG-03-58-007 revealed the presence of a powerful and highly variable disk wind, where two possible phases outflowing with vout1/c ∼ −0.07 and vout2/c ∼ −0.2 were observed. Multi-epoch X-ray observations, covering the period from 2010 to 2018, showed that the lower-velocity component is persistent, as it was detected in all the observations, while the faster phase outflowing with vout2/c ∼ −0.2 appeared to be more sporadic. Here we present the analysis of a new monitoring campaign of MCG-03-58-007 performed in 2019 May–June and consisting of four simultaneous XMM-Newton and NuSTAR observations. We confirm that the disk wind in MCG-03-58-007 is persistent, as it is detected in all the observations, and powerful, having a kinetic power that ranges between 0.5% and 10% of the Eddington luminosity. The highly ionized wind (log(ξ/erg cm s−1) ∼ 5) is variable in both the opacity and, remarkably in its velocity. This is the first time where we have observed a substantial variability of the outflowing velocity in a disk wind, which dropped from vout/c ∼ −0.2 (as measured in the first three observations) to vout/c ∼ −0.074 in just 16 days. We conclude that such a dramatic and fast variability of the outflowing velocity could be due to the acceleration of the wind, as recently proposed by Mizumoto et al. Here, the faster wind, seen in the first three observations, is already accelerated to vout/c ∼ −0.2, while in the last observation our line of sight intercepts only the slower, pre-accelerated streamline.
|
|
| 2. |
- Sjögreen Gleisner, Katarina, et al.
(författare)
-
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
- 2022
-
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 49, s. 1778-1809
-
Tidskriftsartikel (refereegranskat)abstract
- The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.
|
|
